Liver Transplantation from a Human Leukocyte Antigen-Matched Sibling Donor: Effectiveness of Direct-Acting Antiviral Therapy against Hepatitis C Virus Infection.

Autor: Kanda, Tatsuo, Matsumoto, Naoki, Ishii, Tomotaka, Arima, Shuhei, Shibuya, Shinji, Honda, Masayuki, Sasaki-Tanaka, Reina, Masuzaki, Ryota, Kanezawa, Shini, Ogawa, Masahiro, Yamazaki, Shintaro, Aramaki, Osamu, Kogure, Hirofumi, Okamura, Yukiyasu
Předmět:
Zdroj: Reports (MDPI AG); Dec2022, Vol. 5 Issue 4, p49, 9p
Abstrakt: Through living-donor liver transplantation (LDLT) from a human leukocyte antigen (HLA)-matched sibling donor, it may be possible to stop the use of immunosuppressants. It is possible that acute antibody-mediated rejection and chronic active antibody-mediated rejection through the positivity of donor-specific anti-HLA antibodies and/or T cell-mediated rejection may affect the prognosis of liver transplantation. The etiologies of liver diseases of the recipient may also affect the post-transplantation course. Herein, we report on the successful re-treatment with direct-acting antiviral (DAA) therapy against hepatitis C virus (HCV) infection in a patient who underwent a LDLT from HLA-matched sibling donor. After liver transplantation for HCV-related liver diseases, it is easy for HCV to re-infect the graft liver under a lack of immunosuppressants. DAA therapy against HCV re-infection immediately after transplantation should be commenced, and it is important to eradicate HCV for better prognosis of the recipients in LDLT for HCV-related liver diseases. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje